By jurisdiction

United States (FDA)

Every compound we track that has a recorded status under United States (FDA). Tap a name for the full picture, including the U.S. status and primary sources.

CompoundStatus hereNote
BPC-157In limboNot on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted.
CJC-1295In limboRemoved from Category 2 (~Sept 2024); PCAC voted against inclusion Dec 4, 2024; not on the 503A list; no USP monograph.
Emideltide (DSIP)In limboNot on the 503A Bulks List. PCAC voted against adding it on Jul 24, 2026 (6-7, 1 abstention). No further FDA action is scheduled.
EpitalonIn limboNot on the 503A Bulks List. PCAC recommended adding it on Jul 24, 2026 (7-4, 1 abstention); the recommendation is advisory and the FDA has not acted.
GHK-CuIn limboTopical route ≈ Category 1; injectable route removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027.
IpamorelinIn limboRemoved from Category 2 (~Sept 2024); PCAC voted against 503A inclusion Oct 29, 2024; not on any bulks list; no separate ban.
KPVIn limboNot on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted.
Melanotan IIIn limboNot on Category 1 / the 503A list; being moved out of Category 2; PCAC review expected before end of Feb 2027. Not DEA-scheduled.
MOTS-cIn limboNot on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (7-5, 2 abstentions); the recommendation is advisory and the FDA has not acted.
NAD+In limboProposed for non-inclusion (2019); no final rule and no ban; oral sold as a supplement; injectable compounded in a gray area.
SelankIn limboRemoved from Category 2 (~Sept 2024); never in Category 1; not on the 503A list; no scheduled PCAC review.
SemaxIn limboNot on the 503A Bulks List. PCAC recommended adding it on Jul 24, 2026 (8-5, 1 abstention); the recommendation is advisory and the FDA has not acted.
TB-500 (Thymosin Beta-4)In limboNot on the 503A Bulks List. PCAC recommended adding it on Jul 23, 2026 (8-6, 1 abstention); the recommendation is advisory and the FDA has not acted.
Thymosin Alpha-1In limboRemoved from Category 2 (Sept 2024); PCAC declined to recommend it on Dec 4, 2024; not on the 503A list; no approved U.S. product.
CagrilintideRestrictedInvestigational; not approved, not compoundable (not a component of an approved drug, not an eligible bulk substance). The CagriSema NDA is under FDA review; warning letters to sellers, including products sold under coded names.
RetatrutideRestrictedInvestigational; not approved, not compoundable (never on the shortage list, not an eligible bulk substance). FDA warning letters to sellers, including products sold under coded names.
Semaglutide (compounded)RestrictedEnforcement discretion ended Apr 22, 2025 (503A, as announced; the FDA’s Sep 2026 Empower letter dates it Apr 24) / May 22, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow patient-specific 503A exception remains. Sep 18, 2026: FDA warning letter to Empower Pharmacy over semaglutide/B12 injections that appear to be essentially copies.
Tirzepatide (compounded)RestrictedEnforcement discretion ended Feb 18, 2025 (503A, as announced; the FDA’s Sep 2026 Empower letter dates it Mar 5) / Mar 19, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow 503A exception remains. Sep 18, 2026: FDA warning letter to Empower Pharmacy over tirzepatide/niacinamide injections that appear to be essentially copies.
SermorelinCompounding-legalCategory 1 of the interim 503A list; compoundable with a valid prescription under enforcement discretion. Previously approved as Geref.